Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: The ICE trial

Expert Review of Neurotherapeutics

Volumn 9, Issue 6, 2009, Pages 789-795

  Hughes, Richard A C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic inflammatory demyelinating polyradiculoneuropathy; Intravenous immunoglobulin; Randomized, controlled trial

Indexed keywords

HUMAN IMMUNOGLOBULIN; PLACEBO;

ASTHMA; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; GRIP STRENGTH; HEADACHE; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; LUNG EMBOLISM; PHYSICAL DISABILITY; POLYRADICULONEUROPATHY; RELAPSE; REVIEW; SHORT COURSE THERAPY; STROKE; TREATMENT OUTCOME; VOMITING;

CAPRYLATES; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 67649922246     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.30     Document Type: Review

References (29)

1. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 41, 617-618 (1991). • The first and strictest set of diagnostic guidelines for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
2. Chiò A, Cocito D, Bottacchi E, Buffa et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J. Neurol. Neurosurg. Psychiatry 78, 1349-1353 (2007). • Most recent and most comprehensive high quality epidemiological study of CIDP. (Pubitemid 350221415)
3. Joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 10, 220-228 (2005). •• Consensus guidelines for diagnosis and management of CIDP
4. Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl. J. Med. 352, 1343-1356 (2005). • Modern summary of the pathogenesis, diagnosis and management of CIDP.
5. Salomon B, Rhee L, Bour-Jordan H et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J. Exp. Med. 194, 677-684 (2001). (Pubitemid 32844777)
6. Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher. Nerv. Syst. 11, 30-46 (2006). (Pubitemid 43344973)
7. Yan WX, Archelos JJ, Hartung HP, Pollard JD. PO protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 50, 286-292 (2001). (Pubitemid 32848730)
8. Sanvito L, Makowska A, Mahdi-Rogers M et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry 80(3), 333-338 (2009).
9. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 4, CD003280 (2004). • Cochrane systematic review of the evidence for immunosuppressive drugs in CIDP: an update is in press.
10. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291, 2367-2375 (2004). * Review of the evidence and mechanisms of action of intravenous immunoglobulin in neuromuscular disease. (Pubitemid 38656304)
11. Enders U, Toyka KV, Hartung HP, Gold R. Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J. Neuroimmunol. 76, 112-116 (1997). (Pubitemid 27272636)
12. Gabriel CM, Gregson NA, Redford EJ, Davies M, Smith K, Hughes RAC. Human immunoglobulin ameliorates rat experimental autoimmune neuritis (EAN). Brain 120, 1533-1540 (1997). (Pubitemid 27389221)
13. Lin HH, Spies JM, Lu JL, Pollard JD. Effective treatment of experimental autoimmune neuritis with human immunoglobulin. J Neurol. Sci. 256, 61-67 (2007). (Pubitemid 46560627)
14. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry 56, 36-39 (1993). (Pubitemid 23062977)
15. Hahn AF, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind placebo-controlled crossover study. Ann. Neurol. 32, 294-295 (1992).
16. Mendell JR, Barohn RJ, Freimer ML et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56, 445-449 (2001). (Pubitemid 32172866)
17. Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. 243, 280-285 (1996). (Pubitemid 26071992)
18. van Schaik I, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 2, CD001797 (2002). • The Cochrane review on which the Immune Globulin Intravenous CIDP Efficacy (ICE) trial was based. This has been updated: see information resources.
19. Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7, 136-144 (2008). •• The trial discussed in this report.
20. Hughes RAC, Bensa S, Willison HJ et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 50, 195-201 (2001). (Pubitemid 32738144)
21. Bril V, Katzberg H, Donofrio P et al. Electrophysiology in CIDP: results of a clinical treatment trial with IGIV. Muscle Nerve 39(4), 448-455 (2009). • More results from the ICE trial.
22. Merkies ISJ, Bril V, Dalakas MC et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: The ICE Study. Neurology 72(15), 1337-1344 (2009). • More results from the ICE trial.
23. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 60, 1736-1737 (2003). • Important reminder of rare serious adverse events with intravenous immunoglobulin. (Pubitemid 36737065)
24. McCrone P, Chisholm D, Knapp M et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol. 10, 687-694 (2003). (Pubitemid 38030879)
25. Koller H, Schroeter M, Feischen H, Hartung HP, Kieseier BC. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J. Neurol. 253, 1505-1506 (2006). (Pubitemid 44950287)
26. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25, 1256-1264 (2007). (Pubitemid 350076509)
27. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 8, 158-164 (2009). • Largest trial of an immunosuppressant in CIDP did not show a significant beneficial effect.
28. Hirst C, Raasch S, Llewelyn G, Robertson N. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J. Neurol. Neurosurg. Psychiatry 77, 800-802 (2006). (Pubitemid 43837219)
29. The International Inflammatory Neuropathy Consortium www.pnsociety.com/ index.php?option=com-content&view=article&id=59&Itemid=103